Last reviewed · How we verify

Xanax — Competitive Intelligence Brief

Xanax (alprazolam) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzodiazepine (triazolobenzodiazepine). Area: Neuroscience.

marketed Benzodiazepine (triazolobenzodiazepine) Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Xanax (alprazolam) — Generic (originally Upjohn/Pfizer). Short-acting, high-potency benzodiazepine that enhances GABA-A receptor activity, providing rapid anxiolytic relief.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xanax TARGET alprazolam Generic (originally Upjohn/Pfizer) marketed Benzodiazepine (triazolobenzodiazepine) Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4 1981-10-16
Xanax Xanax National Taiwan University Hospital marketed Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzodiazepine (triazolobenzodiazepine) class)

  1. Generic (originally Upjohn/Pfizer) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xanax — Competitive Intelligence Brief. https://druglandscape.com/ci/alprazolam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: